New Delhi, Jun 11 (UNI) Pharma major Lupin Ltd today said the US Food and Drug Administration (FDA) has granted final approval for the company's Abbreviated New Drug Application (ANDA) for Ramipril capsules.
Dosage strengths of 1.25 milligrams, 2.5 mg, 5 mg and 10 mg have been approved, the company said in a statement.
Commercial shipments of the product have already commenced, it added.
Ramipril is the generic equivalent of King Pharmaceuticals Inc's Altace, which had annual sales of about 920 million dollars in 2007.
UNI AK PDT VC1432